Sosei Group acquired all shares of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd. The Transaction also included the assignment of the license on the lead product PIVLAZ® (clazosentan), and all territorial related intellectual property and know-how, as well as license rights to daridorexant for Japan and APAC.

The team of Schellenberg Wittmer consisted of Lorenza Ferrari Hofer (IP / Life Sciences), Tarek Houdrouge (M&A / Capital Markets), Olivier Hari (Lead M&A / Capital Markets), Alexander Zundel (M&A / Capital Markets), Jean-Frédéric Maraia (Taxation), Helen Reinhardt (IP / Life Sciences), and Gian Berner (Trainee Lawyer).